XML 47 R35.htm IDEA: XBRL DOCUMENT
v3.25.1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue | The following table presents a summary of total revenues (in thousands):
|  |  | Three Months Ended March 31, |  |  |  |
|  |  |  |  | 2025 |  | 2024 |  |  |  |
Xywav |  |  |  |  | $ | 344,804 |  |  | $ | 315,300 |  |  |  |  |
Xyrem |  |  |  |  | 37,241 |  |  | 64,232 |  |  |  |  |
Epidiolex/Epidyolex |  |  |  |  | 217,737 |  |  | 198,716 |  |  |  |  |
Sativex |  |  |  |  | 5,407 |  |  | 2,735 |  |  |  |  |
Total Neuroscience |  |  |  |  | 605,189 |  |  | 580,983 |  |  |  |  |
Rylaze/Enrylaze |  |  |  |  | 94,233 |  |  | 102,750 |  |  |  |  |
Zepzelca |  |  |  |  | 63,033 |  |  | 75,100 |  |  |  |  |
Defitelio/defibrotide |  |  |  |  | 40,662 |  |  | 47,676 |  |  |  |  |
Vyxeos |  |  |  |  | 29,544 |  |  | 32,023 |  |  |  |  |
Ziihera |  |  |  |  | 1,975 |  |  | — |  |  |  |  |
Total Oncology |  |  |  |  | 229,447 |  |  | 257,549 |  |  |  |  |
Other |  |  |  |  | 4,782 |  |  | 3,570 |  |  |  |  |
Product sales, net |  |  |  |  | 839,418 |  |  | 842,102 |  |  |  |  |
High-sodium oxybate AG royalty revenue |  |  |  |  | 48,946 |  |  | 49,947 |  |  |  |  |
Other royalty and contract revenues |  |  |  |  | 9,477 |  |  | 9,934 |  |  |  |  |
Total revenues |  |  |  |  | $ | 897,841 |  |  | $ | 901,983 |  |  |  |  |
The following table presents a summary of total revenues attributed to geographic sources (in thousands):
|  |  | Three Months Ended March 31,
|  |  |  |  | 2025 |  | 2024
United States |  |  |  |  | $ | 797,945 |  |  | $ | 808,214 |
Europe |  |  |  |  | 83,607 |  |  | 71,355 |
All other |  |  |  |  | 16,289 |  |  | 22,414 |
Total revenues |  |  |  |  | $ | 897,841 |  |  | $ | 901,983 |
Schedule of Percentage of Total Revenues from Customers | The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:
|  |  | Three Months Ended March 31,
|  |  |  |  | 2025 |  | 2024
ESSDS |  |  |  |  | 42 | % |  | 42 | %
ASD |  |  |  |  | 12 | % |  | 6 | %
McKesson |  |  |  |  | 11 | % |  | 12 | %

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration